Show simple item record

dc.contributor.authorBadr, Aisha F
dc.contributor.authorKurdi, Sawsan
dc.contributor.authorAlshehri, Samah
dc.contributor.authorMcManus, Claire
dc.contributor.authorLee, Jeannie
dc.date.accessioned2019-05-09T20:28:21Z
dc.date.available2019-05-09T20:28:21Z
dc.date.issued2018-12-01
dc.identifier.citationBadr, A. F., Kurdi, S., Alshehri, S., McManus, C., & Lee, J. (2018). Pharmacists' interventions to reduce sedative/hypnotic use for insomnia in hospitalized patients. Saudi pharmaceutical journal, 26(8), 1204-1207.en_US
dc.identifier.issn1319-0164
dc.identifier.pmid30510473
dc.identifier.doi10.1016/j.jsps.2018.07.010
dc.identifier.urihttp://hdl.handle.net/10150/632223
dc.description.abstractBackground: Hospitalization can contribute to insomnia in many patients and is usually treated symptomatically. However, sedative/hypnotic misuse is associated with complications in this population, especially in the elderly. Such complications include dizziness, falls and over-sedation. Due to the implicit dangers, widespread use of these drugs for insomnia, particularly in older patients, has been discouraged by many hospitals. The aim of this study was to review and evaluate prescribing patterns and to optimize the use of the sedative/hypnotic agents through daily pharmacy interventions at a community hospital. Methods: This was a biphasic before and after study. Data on sedative/hypnotic use was collected retrospectively for a 2-month period and a sample of 100 patients was randomly selected for analysis. A 2-month prospective phase followed, in which daily orders were reviewed by one pharmacy resident and recommendations made to discontinue any unnecessary, newly prescribed sedative/hypnotic orders when appropriate. Finally, results of both phases were compared for any differences in patient demographics, being prescribed more than one sedative/hypnotic, and complications documented. Results: During the prospective phase, pharmacist interventions led to the discontinuation of 25% of a total of 97 sedative/hypnotic orders in 97 patients. The number of patients receiving more than one sedative/hypnotic agents in the intervention group was significantly lower than the retrospective control group (15 Vs. 34, P = 0.0026). The incidence of complications was not significantly different between the control and intervention groups for the following: over-sedation, falls and delirium (p = 0.835, p = 0.185, p = 0.697, respectively). Conclusion: This study suggests that the use of sedative/hypnotics in the inpatient units (excluding the critical care unit), is somewhat prevalent, and many patients may be on more than one sedative/hypnotic, which could potentially cause cumulative harm. During the intervention phase, 25% of the total in-hospital orders for sedative/hypnotics were discontinued following recommendations made by a pharmacist, and significantly lower number of patients receiving duplicate sedative/hypnotics was noted. Further efforts should be implemented to avoid unnecessary sedative/hypnotic initiation in hospitalized patients, and to ensure monitoring by pharmacists is optimized. (C) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.en_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE BVen_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S1319016418301518?via%3Dihuben_US
dc.rights© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectClinical pharmacyen_US
dc.subjectGeriatricsen_US
dc.subjectInternal medicineen_US
dc.subjectMedication errorsen_US
dc.subjectMedication safetyen_US
dc.subjectSleep disordersen_US
dc.titlePharmacists' interventions to reduce sedative/hypnotic use for insomnia in hospitalized patientsen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Pharmen_US
dc.identifier.journalSAUDI PHARMACEUTICAL JOURNALen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
refterms.dateFOA2019-05-09T20:28:22Z


Files in this item

Thumbnail
Name:
1-s2.0-S1319016418301518-main.pdf
Size:
440.9Kb
Format:
PDF
Description:
Final Published version

This item appears in the following Collection(s)

Show simple item record

© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as © 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).